Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Paris, France, March 28th 2018 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
The filing is based on the results of the global placebo-controlled phase 3 CELESTIAL trial which met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant improvement and clinically meaningful improvement in median OS compared with placebo in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.
Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen, said:
“This milestone is an important step forward for the cabozantinib ongoing development program
across solid tumors, with the potential, if approved, to provide patients with advanced HCC – which is still an unmet medical need – with a new oral systemic treatment.”
Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Paris, France, March 28th 2018 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
The filing is based on the results of the global placebo-controlled phase 3 CELESTIAL trial which met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant improvement and clinically meaningful improvement in median OS compared with placebo in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.
Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen, said:
“This milestone is an important step forward for the cabozantinib ongoing development program
across solid tumors, with the potential, if approved, to provide patients with advanced HCC – which is still an unmet medical need – with a new oral systemic treatment.”
Related Press Releases
![Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
![Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
![Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
![Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
![Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
![Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
![Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
![Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
![Ipsen appoints Keira Driansky as EVP, President of North America Ipsen appoints Keira Driansky as EVP, President of North America](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)